Browse by Nurse Practitioner Items

Nurse practitioner PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED NURSE PRACTITIONERS

From 1 September 2010, nurse practitioners endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (authorised nurse practitioners) Information for nurse practitioners to become authorised PBS prescribers is available from Services Australia.

The medicines listed for prescribing by authorised nurse practitioners from 1 November 2010 are identified by ‘NP’ in the PBS Schedule. Nurse practitioners must not write PBS prescriptions for other medicines.

PBS prescribing is limited by a nurse practitioner’s scope of practice, and state and territory prescribing rights. Prescribing of PBS medicines is also contingent on a prescriber being an authorised nurse practitioner and having collaborative arrangements in place, as required by amendments to the National Health Act 1953.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health regarding medicines for prescribing by authorised nurse practitioners.

Further to prescribing within collaborative arrangements, certain medicines also have additional conditions for prescribing by nurse practitioners, as recommended by the PBAC. These medicines are identified by the codes ‘CTO’ for continuation therapy only or ‘SCM’ for prescribing within a shared care model, as outlined below:

  • Continuing therapy only model

Where the patient’s treatment and prescribing of a medicine has been initiated by a medical practitioner, but prescribing is continued by a nurse practitioner. (This is similar to existing arrangements between specialists and medical practitioners for prescribing certain medicines.)

  • Shared care model

Where care is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed plan to manage the patient, in a patientcentred model of care. The details surrounding shared care arrangements will depend on the practitioners involved, patient needs and the healthcare context.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Nurse practitioner PBS prescriptions are identifiable by colour, and include the indicator ‘NP’ on personalised forms and a tick box on non-personalised (blank) forms.

Prescriptions must include the nurse practitioner’s PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms.  For authority required and authority required (streamlined) PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms.  Nurse practitioner PBS prescriptions may include repeats. 

Regulation 49 applies for nurse practitioner prescribing. A nurse practitioner can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from Services Australia for each prescription. (Refer to Prescribing Medicines — Information for PBS prescribers and Supplying medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and territory requirements: Nurse practitioners may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the nurse practitioner’s responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

  • Legend
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MPNP 11123K SACUBITRIL + VALSARTANsacubitril 24.3 mg + valsartan 25.7 mg tablet, 56 1 56 5
MPNP 13570F SACUBITRIL + VALSARTANsacubitril 24.3 mg + valsartan 25.7 mg tablet, 56 2 112 5
MPNP 11131W SACUBITRIL + VALSARTANsacubitril 48.6 mg + valsartan 51.4 mg tablet, 56 1 56 5
MPNP 13511D SACUBITRIL + VALSARTANsacubitril 48.6 mg + valsartan 51.4 mg tablet, 56 2 112 5
MPNP 11122J SACUBITRIL + VALSARTANsacubitril 97.2 mg + valsartan 102.8 mg tablet, 56 1 56 5
MPNP 13445P SACUBITRIL + VALSARTANsacubitril 97.2 mg + valsartan 102.8 mg tablet, 56 2 112 5
MPNP 11656L SAFINAMIDEsafinamide 50 mg tablet, 30 1 30 5
MPNP 11666B SAFINAMIDEsafinamide 100 mg tablet, 30 1 30 5
MPNP 11125M SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 1 1 0
MPNP 13821K SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 3 3 5
MPNP 13828T SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 1 1 0
MPNP 11130T SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 3 3 5
MPNP 11088N SALBUTAMOLsalbutamol 5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 1 1 0
MPNP 11095Y SALBUTAMOLsalbutamol 5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules 3 3 5
MPNP 2000G SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 30 x 2.5 mL ampoules 2 2 5
MPNP 3496B SALBUTAMOLsalbutamol 2.5 mg/2.5 mL inhalation solution, 30 x 2.5 mL ampoules 1 1 0
MPNP 2001H SALBUTAMOLsalbutamol 5 mg/2.5 mL inhalation solution, 30 x 2.5 mL ampoules 2 2 5
MPNP 3497C SALBUTAMOLsalbutamol 5 mg/2.5 mL inhalation solution, 30 x 2.5 mL ampoules 1 1 0
MPNP 8354Q SALBUTAMOLsalbutamol 100 microgram/actuation breath activated inhalation, 200 actuations 2 2 5
MPNP 1103C SALBUTAMOLsalbutamol 2 mg/5 mL oral liquid, 150 mL 2 2 5
MPNP 12108G SALBUTAMOLsalbutamol 100 microgram/actuation inhalation, 200 actuations 1 1 0
MPNP 12109H SALBUTAMOLsalbutamol 100 microgram/actuation inhalation, 200 actuations 2 2 5
MPNP 8141L SALMETEROLsalmeterol 50 microgram/actuation powder for inhalation, 60 actuations 1 1 5
MPNP 11970B SAPROPTERINsapropterin dihydrochloride 500 mg powder for oral liquid, 30 sachets 1 30 5
MPNP 11983Q SAPROPTERINsapropterin dihydrochloride 500 mg powder for oral liquid, 30 sachets 1 30 5
MPNP 10087X SAPROPTERINsapropterin dihydrochloride 100 mg soluble tablet, 30 6 180 5
MPNP 11691H SAPROPTERINsapropterin dihydrochloride 100 mg soluble tablet, 30 6 180 5
MPNP 12569M SAPROPTERINsapropterin dihydrochloride 100 mg soluble tablet, 30 1 30 5
MPNP 13923T SAXAGLIPTINsaxagliptin 5 mg tablet, 28 2 56 5
MPNP 8983T SAXAGLIPTINsaxagliptin 5 mg tablet, 28 1 28 5
MPNP 10128C SAXAGLIPTINsaxagliptin 2.5 mg tablet, 28 1 28 5
MPNP 13895H SAXAGLIPTINsaxagliptin 2.5 mg tablet, 28 2 56 5
MPNP 11305B SAXAGLIPTIN + DAPAGLIFLOZINsaxagliptin 5 mg + dapagliflozin 10 mg tablet, 28 1 28 5
MPNP 13855F SAXAGLIPTIN + DAPAGLIFLOZINsaxagliptin 5 mg + dapagliflozin 10 mg tablet, 28 2 56 5
MPNP 10055F SAXAGLIPTIN + METFORMINsaxagliptin 5 mg + metformin hydrochloride 500 mg modified release tablet, 28 1 28 5
MPNP 14030K SAXAGLIPTIN + METFORMINsaxagliptin 5 mg + metformin hydrochloride 500 mg modified release tablet, 28 2 56 5
MPNP 10051B SAXAGLIPTIN + METFORMINsaxagliptin 5 mg + metformin hydrochloride 1 g modified release tablet, 28 1 28 5
MPNP 13876H SAXAGLIPTIN + METFORMINsaxagliptin 5 mg + metformin hydrochloride 1 g modified release tablet, 28 2 56 5
MPNP 10048W SAXAGLIPTIN + METFORMINsaxagliptin 2.5 mg + metformin hydrochloride 1 g modified release tablet, 56 1 56 5
MPNP 13880M SAXAGLIPTIN + METFORMINsaxagliptin 2.5 mg + metformin hydrochloride 1 g modified release tablet, 56 2 112 5
MPNP 1973W SELEGILINEselegiline hydrochloride 5 mg tablet, 100 1 100 5
MPNP 12080T SEMAGLUTIDEsemaglutide 1.34 mg/mL injection, 1 x 1.5 mL pen device 1 1 5
MPNP 12075M SEMAGLUTIDEsemaglutide 1.34 mg/mL injection, 1 x 3 mL pen device 1 1 5
MPNP 2237R SERTRALINEsertraline 100 mg tablet, 30 1 30 5
MPNP 8837D SERTRALINEsertraline 100 mg tablet, 30 1 30 5
MPNP 2236Q SERTRALINEsertraline 50 mg tablet, 30 1 30 5
MPNP 8836C SERTRALINEsertraline 50 mg tablet, 30 1 30 5
MPNP 13934J SEVELAMERsevelamer hydrochloride 800 mg tablet, 180 2 360 5
MPNP 2142R SEVELAMERsevelamer hydrochloride 800 mg tablet, 180 1 180 5
MPNP 11856B SEVELAMERsevelamer carbonate 800 mg tablet, 180 1 180 5
MPNP 14027G SEVELAMERsevelamer carbonate 800 mg tablet, 180 2 360 5
MPNP 9479X SILVER SULFADIAZINEsilver sulfadiazine 1% cream, 50 g 1 1 0
MPNP 13528B SIMVASTATINsimvastatin 10 mg tablet, 30 2 60 5
MPNP 2011W SIMVASTATINsimvastatin 10 mg tablet, 30 1 30 5
MPNP 13373W SIMVASTATINsimvastatin 20 mg tablet, 30 2 60 5
MPNP 2012X SIMVASTATINsimvastatin 20 mg tablet, 30 1 30 5
MPNP 13471B SIMVASTATINsimvastatin 40 mg tablet, 30 2 60 5
MPNP 8173E SIMVASTATINsimvastatin 40 mg tablet, 30 1 30 5
MPNP 13559P SIMVASTATINsimvastatin 5 mg tablet, 30 2 60 5
MPNP 2013Y SIMVASTATINsimvastatin 5 mg tablet, 30 1 30 5
MPNP 13498K SIMVASTATINsimvastatin 80 mg tablet, 30 2 60 5
MPNP 8313M SIMVASTATINsimvastatin 80 mg tablet, 30 1 30 5
MPNP 13871C SITAGLIPTINsitagliptin 100 mg tablet, 28 2 56 5
MPNP 9182G SITAGLIPTINsitagliptin 100 mg tablet, 28 1 28 5
MPNP 14021Y SITAGLIPTINsitagliptin 25 mg tablet, 28 2 56 5
MPNP 9180E SITAGLIPTINsitagliptin 25 mg tablet, 28 1 28 5
MPNP 14058X SITAGLIPTINsitagliptin 50 mg tablet, 28 2 56 5
MPNP 9181F SITAGLIPTINsitagliptin 50 mg tablet, 28 1 28 5
MPNP 10090C SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 1 g modified release tablet, 56 1 56 5
MPNP 13990H SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 1 g modified release tablet, 56 2 112 5
MPNP 10089B SITAGLIPTIN + METFORMINsitagliptin 100 mg + metformin hydrochloride 1 g tablet: modified release, 28 1 28 5
MPNP 14031L SITAGLIPTIN + METFORMINsitagliptin 100 mg + metformin hydrochloride 1 g tablet: modified release, 28 2 56 5
MPNP 14035Q SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 1 g tablet, 56 2 112 5
MPNP 9451K SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 1 g tablet, 56 1 56 5
MPNP 13994M SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 500 mg tablet, 56 2 112 5
MPNP 9449H SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 500 mg tablet, 56 1 56 5
MPNP 14064F SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 850 mg tablet, 56 2 112 5
MPNP 9450J SITAGLIPTIN + METFORMINsitagliptin 50 mg + metformin hydrochloride 850 mg tablet, 56 1 56 5
MPNP 3196F SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE + CITRIC ACIDsodium chloride 470 mg + potassium chloride 300 mg (potassium 4 mmol) + glucose monohydrate 3.56 g + sodium acid citrate 530 mg powder for oral liquid, 10 x 4.9 g sachets 1 1 0
MPNP 11865L SODIUM PHENYLBUTYRATEsodium phenylbutyrate 483 mg/g granules, 174 g 3 3 5
MPNP 11144M SOFOSBUVIR + VELPATASVIRsofosbuvir 400 mg + velpatasvir 100 mg tablet, 28 1 28 2
MPNP 11145N SOFOSBUVIR + VELPATASVIRsofosbuvir 400 mg + velpatasvir 100 mg tablet, 28 1 28 2
MPNP 11147Q SOFOSBUVIR + VELPATASVIRsofosbuvir 400 mg + velpatasvir 100 mg tablet, 28 1 28 2
MPNP 11658N SOFOSBUVIR + VELPATASVIR + VOXILAPREVIRsofosbuvir 400 mg + velpatasvir 100 mg + voxilaprevir 100 mg tablet, 28 1 28 2
MPNP 11659P SOFOSBUVIR + VELPATASVIR + VOXILAPREVIRsofosbuvir 400 mg + velpatasvir 100 mg + voxilaprevir 100 mg tablet, 28 1 28 2
MPNP 11665Y SOFOSBUVIR + VELPATASVIR + VOXILAPREVIRsofosbuvir 400 mg + velpatasvir 100 mg + voxilaprevir 100 mg tablet, 28 1 28 2
MPNP 8398B SOTALOLsotalol hydrochloride 80 mg tablet, 60 1 60 5
MPNP 2043M SOTALOLsotalol hydrochloride 160 mg tablet, 60 1 60 5
MPNP 9448G SOY LECITHIN + TOCOPHEROL + VITAMIN Asoy lecithin 1% + tocopherol 0.002% + vitamin A palmitate 0.025% spray, 100 actuations 2 2 5
MPNP 8577K SOY PROTEIN AND FAT FORMULA WITH VITAMINS AND MINERALS CARBOHYDRATE FREEsoy protein and fat formula with vitamins and minerals carbohydrate free oral liquid, 384 mL can 120 120 5
MPNP 2340E SPIRONOLACTONEspironolactone 100 mg tablet, 100 1 100 5
MPNP 14042C SPIRONOLACTONEspironolactone 100 mg tablet, 100 2 200 5
MPNP 2339D SPIRONOLACTONEspironolactone 25 mg tablet, 100 1 100 5
MPNP 13503Q SPIRONOLACTONEspironolactone 25 mg tablet, 100 2 200 5
MPNP 10250L SUCROFERRIC OXYHYDROXIDEsucroferric oxyhydroxide 2.5 g (iron 500 mg) chewable tablet, 90 1 90 5
MPNP 13985C SUCROFERRIC OXYHYDROXIDEsucroferric oxyhydroxide 2.5 g (iron 500 mg) chewable tablet, 90 2 180 5
MPNP 13557M SULFASALAZINEsulfasalazine 500 mg tablet, 100 4 400 5
MPNP 2093E SULFASALAZINEsulfasalazine 500 mg tablet, 100 2 200 5
MPNP 13433B SULFASALAZINEsulfasalazine 500 mg enteric tablet, 100 4 400 5
MPNP 2096H SULFASALAZINEsulfasalazine 500 mg enteric tablet, 100 2 200 5
MPNP 14016Q SULTHIAMEsulthiame 200 mg tablet, 200 2 400 2
MPNP 2100M SULTHIAMEsulthiame 200 mg tablet, 200 1 200 2
MPNP 13916K SULTHIAMEsulthiame 50 mg tablet, 200 2 400 2
MPNP 2099L SULTHIAMEsulthiame 50 mg tablet, 200 1 200 2
MPNP 1849H SUMATRIPTANsumatriptan 50 mg tablet, 4 1 4 5
MPNP 8144P SUMATRIPTANsumatriptan 50 mg tablet, 2 2 4 5
MPNP 10694W SUMATRIPTANSUMATRIPTAN Tablet 50 mg (base) (fast disintegrating), 4 1 4 5
MPNP 8341B SUMATRIPTANsumatriptan 20 mg/actuation nasal spray, 2 x 1 actuation 1 2 5